153 related articles for article (PubMed ID: 6497565)
1. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
Whalley LJ; Christie JE; Brown S; Arbuthnott GW
Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
[TBL] [Abstract][Full Text] [Related]
2. Noradrenergic and dopaminergic interrelation in schizophrenia.
Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
[TBL] [Abstract][Full Text] [Related]
4. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
[TBL] [Abstract][Full Text] [Related]
5. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.
Zemlan FP; Hirschowitz J; Garver DL
Arch Gen Psychiatry; 1986 Dec; 43(12):1162-7. PubMed ID: 3778112
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
7. A major flaw in the diagnosis of schizophrenia: what happened to the Schneider's first rank symptoms.
Moscarelli M
Psychol Med; 2020 Jul; 50(9):1409-1417. PubMed ID: 32524921
[TBL] [Abstract][Full Text] [Related]
8. Hormonal effects of apomorphine in schizophrenia.
Ferrier IN; Johnstone EC; Crow TJ
Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
[TBL] [Abstract][Full Text] [Related]
10. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
[TBL] [Abstract][Full Text] [Related]
11. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal instability of hormone responses in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):545-9. PubMed ID: 6686692
[TBL] [Abstract][Full Text] [Related]
13. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
[TBL] [Abstract][Full Text] [Related]
14. Dopamine and serotonin function in untreated schizophrenia: clinical correlates of the apomorphine and d-fenfluramine tests.
Duval F; Mokrani MC; Monreal J; Bailey P; Valdebenito M; Crocq MA; Macher JP
Psychoneuroendocrinology; 2003 Jul; 28(5):627-42. PubMed ID: 12727131
[TBL] [Abstract][Full Text] [Related]
15. Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Prevalence and clinical correlates.
Lieberman JA; Jody D; Alvir JM; Ashtari M; Levy DL; Bogerts B; Degreef G; Mayerhoff DI; Cooper T
Arch Gen Psychiatry; 1993 May; 50(5):357-68. PubMed ID: 8489325
[TBL] [Abstract][Full Text] [Related]
16. Prolactin and growth hormone responses to growth hormone-releasing hormone in acute schizophrenia.
Nerozzi D; Magnani A; Sforza V; Scaramucci E; Cerilli M; Moretti C; Antonozzi I; Frajese G
Neuropsychobiology; 1990; 23(1):15-7. PubMed ID: 2280826
[TBL] [Abstract][Full Text] [Related]
17. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
[TBL] [Abstract][Full Text] [Related]
18. Multihormonal responses to apomorphine in mental illness.
Mokrani MC; Duval F; Crocq MA; Bailey PE; Macher JP
Psychoneuroendocrinology; 1995; 20(4):365-75. PubMed ID: 8532820
[TBL] [Abstract][Full Text] [Related]
19. Reduced growth hormone response to apomorphine in schizophrenic patients with poor premorbid social functioning.
Malas KL; van Kammen DP; de Fraites EA; Brown GM; Gold PW
J Neural Transm; 1987; 69(3-4):319-24. PubMed ID: 3625198
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
